Arbutus Biopharma Corp
ABUS
Rank in Stocks
#10154
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company,... Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Share Price
$3.72
Last synced: 2026-11-09
Market Cap
$736.95M
Change (1 day)
1.78%
Change (1 year)
-23.14%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Arbutus Biopharma Corp (ABUS)
Category
Healthcare
EPS for Arbutus Biopharma Corp (ABUS)
EPS as of June 2026 TTM: $0.79
According to Arbutus Biopharma Corp's latest financial reports, its current EPS (TTM) is $0.79. At the end of 2025 the company had an EPS of $-0.17, an increase over its 2024 EPS of $-0.38.
EPS history for Arbutus Biopharma Corp from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.79 | -564.71% |
| 2025 | $-0.17 | -55.26% |
| 2024 | $-0.38 | -13.64% |
| 2023 | $-0.44 | -4.35% |
| 2022 | $-0.46 | -36.99% |
| 2021 | $-0.73 | -15.12% |
| 2020 | $-0.86 | -68.03% |
| 2019 | $-2.69 | 161.17% |
| 2018 | $-1.03 | -33.12% |
| 2017 | $-1.54 | -78.73% |
| 2016 | $-7.24 | 440.30% |
| 2015 | $-1.34 | -25.56% |
| 2014 | $-1.80 | 95.65% |
| 2013 | $-0.92 | -142.59% |
| 2012 | $2.16 | -351.16% |
| 2011 | $-0.86 | -28.33% |
| 2010 | $-1.20 | 33.33% |
| 2009 | $-0.90 | -37.50% |
| 2008 | $-1.44 | 166.67% |
| 2007 | $-0.54 | -111.54% |
| 2006 | $4.68 | -550.00% |
| 2005 | $-1.04 | -71.43% |
| 2004 | $-3.64 | -23.85% |
| 2003 | $-4.78 | 17.16% |
| 2002 | $-4.08 | 47.83% |
| 2001 | $-2.76 | 47.59% |
| 2000 | $-1.87 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 1,882.28% |
US
|
|
| $-7.07 | -994.94% |
US
|
|
| $-5.29 | -769.62% |
AU
|
|
| $12.88 | 1,530.39% |
BE
|
|
| $21.56 | 2,629.11% |
NL
|
Questions about Arbutus Biopharma Corp's earnings per share (EPS)
What is Arbutus Biopharma Corp's earnings per share (EPS)?
Arbutus Biopharma Corp's earnings per share (EPS) over the last twelve months is $0.79, as of Jun 2026.
What was Arbutus Biopharma Corp's earnings per share (EPS) in 2025?
In 2025, Arbutus Biopharma Corp's earnings per share (EPS) was $-0.17, compared with $-0.38 in 2024.
How has Arbutus Biopharma Corp's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Arbutus Biopharma Corp's earnings per share (EPS) was highest in 2025 ($-0.17) and lowest in 2020 ($-0.86).
How does Arbutus Biopharma Corp's earnings per share (EPS) compare with similar companies?
Arbutus Biopharma Corp's earnings per share (EPS) ($0.79) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.